U.S. Markets closed
  • S&P Futures

    4,134.50
    -11.75 (-0.28%)
     
  • Dow Futures

    34,082.00
    -101.00 (-0.30%)
     
  • Nasdaq Futures

    13,288.50
    -57.50 (-0.43%)
     
  • Russell 2000 Futures

    2,192.50
    -10.80 (-0.49%)
     
  • Crude Oil

    65.31
    +0.03 (+0.05%)
     
  • Gold

    1,826.80
    -9.30 (-0.51%)
     
  • Silver

    27.43
    -0.24 (-0.86%)
     
  • EUR/USD

    1.2133
    -0.0019 (-0.1577%)
     
  • 10-Yr Bond

    1.6240
    +0.0220 (+1.37%)
     
  • Vix

    21.84
    +2.18 (+11.09%)
     
  • GBP/USD

    1.4114
    -0.0030 (-0.2131%)
     
  • USD/JPY

    108.8700
    +0.2500 (+0.2302%)
     
  • BTC-USD

    57,264.14
    +2,448.34 (+4.47%)
     
  • CMC Crypto 200

    1,550.39
    +1,307.71 (+538.86%)
     
  • FTSE 100

    6,947.99
    -175.69 (-2.47%)
     
  • Nikkei 225

    28,439.52
    -169.07 (-0.59%)
     

Here's Why We're Not Too Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn Situation

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?

So, the natural question for Fennec Pharmaceuticals (NASDAQ:FENC) shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

Check out our latest analysis for Fennec Pharmaceuticals

When Might Fennec Pharmaceuticals Run Out Of Money?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at June 2020, Fennec Pharmaceuticals had cash of US$39m and no debt. Looking at the last year, the company burnt through US$11m. That means it had a cash runway of about 3.6 years as of June 2020. There's no doubt that this is a reassuringly long runway. The image below shows how its cash balance has been changing over the last few years.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Fennec Pharmaceuticals' Cash Burn Changing Over Time?

Fennec Pharmaceuticals didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. Over the last year its cash burn actually increased by 9.4%, which suggests that management are increasing investment in future growth, but not too quickly. However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Easily Can Fennec Pharmaceuticals Raise Cash?

While its cash burn is only increasing slightly, Fennec Pharmaceuticals shareholders should still consider the potential need for further cash, down the track. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Since it has a market capitalisation of US$207m, Fennec Pharmaceuticals' US$11m in cash burn equates to about 5.2% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

So, Should We Worry About Fennec Pharmaceuticals' Cash Burn?

As you can probably tell by now, we're not too worried about Fennec Pharmaceuticals' cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. Taking an in-depth view of risks, we've identified 2 warning signs for Fennec Pharmaceuticals that you should be aware of before investing.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.